St Vincent's Hospital

Running trials

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  NCT06465069· Phase 1· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· Source

• Recruiting

  FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  NCT05614739· Phase 1· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Source

• Active, not recruiting

  A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

  NCT04975308· Phase 3· Source

• Active, not recruiting

  Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

  NCT04319783· Phase 2· Source

• Recruiting

  Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  NCT04614103· Phase 2· Source

• Active, not recruiting

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· Phase 3· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer3 recruiting
• Cervical cancer2 recruiting
• Head and neck cancer2 recruiting
• Lung cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

  NCT05867121· Phase 1· Source

• Terminated

  Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT04918810· Phase 2· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source